TGFB1 and neoplasm: Preclinical studies supported this approach by showing that dual inhibition of PD-L1 and TGF-β fosters an inflamed tumor phenotype, enhances antigen presentation, and augments infiltration and activation of cytotoxic T cells and NK cells [25].